[Smoking cessation program based on pharmacological support (bupropion SR). Our own experience]

Abstract
Smoking constitutes the gravest, yet avoidable, deadly threat to health in Poland. Near the end of the 90-ies it was discovered that the antidepressant -bupropion- has positive effects in the treatment of addiction to nicotine. The aim of the study was the evaluation of the efficacy of ambulatory, intensive smoking cessation program based on bupropion SR with educational support. 54 smokers (18 men and 36 women) were enrolled, age 22-59 yr. (mean 45.5 +/- 8.7), smoking 10-50 cigarettes daily. Early abstinence rate (7 weeks after quitting) was 61.1%, after 6 months 45.2% of the participants were still non-smokers. The most common adverse effects of bupropion SR therapy were mouth dryness and sleep disturbances, 13% of patients had to stop using bupropion because of side effects. High percentage of abstinence indicates that intensive smoking cessation programs should be used as a part of antinicotine strategy. The pharmacological support in the nicotine dependence treatment should be performed under careful physician supervision.
  • [Show abstract] [Hide abstract] ABSTRACT: Stopping smoking is the only known method to slow down the inevitable progression of COPD. Early detection of the disease in smokers at risk of COPD gives a unique opportunity to prevent the disease progression. The aim of the study was to evaluate the effects of smoking intervention in a group of subjects with newly diagnosed airflow limitation (AL). Of 558 current smokers participating in population spirometric screening for COPD combined with smoking cessation advice, 297 were diagnosed to have AL (FEV1/FVC < 0.7). After one year 193 presented for follow-up visit. Thirty subjects (10.1%) quit smoking. Remaining 163 smokers were invited to smokers' clinic. Attendees (n = 70), 40 males, and 30 females, mean age 56 years, were randomized at visit 1 to treatment with nicotine patch (n = 38) or bupropion SR (n = 32). Follow-up was scheduled at 2 weeks, at the end of treatment, 6 months and 12 months. After 12 months a phone call assessed the smoking status. Non smoking was validated with carbon monoxide measurements in exhaled air. Patients who did not attend the follow-up visits were considered smokers. The number of participants at follow-up decreased significantly: from 70 subjects at visit one to 57 after 2 weeks, 34 at end of treatment and 14 subjects at months. Almost all (n = 69) were reached at 12 month by the phone. The validated quit rate after 12 months was 18.5% (13/70), 8 in group treated with nicotine patch and 5 in the group treated with bupropion SR (NS). When total group of smokers with newly diagnosed COPD was considered 10% quit smoking as result of minimal intervention with another 4.5% after pharmacological treatment.
    Article · Jan 2003
  • [Show abstract] [Hide abstract] ABSTRACT: Tobacco dependence is a chronic, relapsing disease causing an enormous burden of deaths. The aim of the study was a one year evaluation of the efficacy of bupropion SR supported by an educational program in the treatment of nicotine dependence and analysis of the reasons of relapses. 54 smokers were enrolled. The 12-month continuous abstinence rate was 28.3%. The most common cause of relapses in the treatment period was craving for cigarettes, in the post-treatment period stress.
    Article · Feb 2004
  • [Show abstract] [Hide abstract] ABSTRACT: The purpose of this paper was to investigate the efficacy of bupropion and varenicline for treating nicotine dependence as reported in the published studies. We analysed 435 journal articles identified in Pubmed data base with "nicotine, dependence, bupropion / varencline" included in abstract. The "human" filter was applied. 20 efficacy studies were selected and included for evaluation in this review. The results of these studies support the efficacy of both bupropion and varenicline, with varenicline showing higher abstinence rates. However in real life settings high levels of efficacy are lacking for all current available treatments. In addition, treatment related side effects highly influence the patient compliance.
    Article · Jan 2015

Recommended publications

Discover more